Triple Negative Breast Neoplasms
"Triple Negative Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Descriptor ID |
D064726
|
| MeSH Number(s) |
C04.588.180.788 C17.800.090.500.788
|
| Concept/Terms |
Triple Negative Breast Neoplasms- Triple Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Neoplasms
- ER Negative PR Negative HER2 Negative Breast Neoplasms
- Triple-Negative Breast Cancer
- Breast Cancer, Triple-Negative
- Breast Cancers, Triple-Negative
- Triple-Negative Breast Cancers
- Triple-Negative Breast Neoplasm
- Breast Neoplasm, Triple-Negative
- Breast Neoplasms, Triple-Negative
- Triple Negative Breast Neoplasm
- Triple-Negative Breast Neoplasms
- ER-Negative PR-Negative HER2-Negative Breast Cancer
- ER Negative PR Negative HER2 Negative Breast Cancer
- Triple Negative Breast Cancer
|
Below are MeSH descriptors whose meaning is more general than "Triple Negative Breast Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Triple Negative Breast Neoplasms".
This graph shows the total number of publications written about "Triple Negative Breast Neoplasms" by people in this website by year, and whether "Triple Negative Breast Neoplasms" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 10 | 1 | 11 |
| 2014 | 21 | 8 | 29 |
| 2015 | 15 | 4 | 19 |
| 2016 | 35 | 7 | 42 |
| 2017 | 25 | 6 | 31 |
| 2018 | 30 | 6 | 36 |
| 2019 | 27 | 5 | 32 |
| 2020 | 35 | 5 | 40 |
| 2021 | 43 | 2 | 45 |
| 2022 | 36 | 1 | 37 |
| 2023 | 26 | 0 | 26 |
| 2024 | 23 | 6 | 29 |
| 2025 | 2 | 1 | 3 |
Below are the most recent publications written about "Triple Negative Breast Neoplasms" by people in Profiles.
-
Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. Cell Rep Med. 2025 Feb 18; 6(2):101941.
-
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):403-413.
-
Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors. Breast Cancer Res. 2025 Jan 16; 27(1):8.
-
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat. 2025 Feb; 210(1):179-189.
-
The TRIM37 variant rs57141087 contributes to triple-negative breast cancer outcomes in Black women. EMBO Rep. 2025 Jan; 26(1):245-272.
-
Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer. Cancer Res. 2024 Oct 01; 84(19):3250-3266.
-
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2024 Dec 20; 42(36):4282-4293.
-
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024 Aug 30; 12(8).
-
Differential Abundance of DNA Damage Sensors and Innate Immune Signaling Proteins in Inositol Polyphosphate 4-Phosphatase Type II-Negative Triple-Negative Breast Cancer Classified by Immunotype. Am J Pathol. 2024 Nov; 194(11):2212-2232.
-
Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review. Med Oncol. 2024 Aug 09; 41(9):222.